To functionally demonstrate that the identified CEs act as EGFR enhancers in glioblastoma, we introduced targeted perturbations utilising both CRISPRi (dCas9-KRAB) and CRISPR/Cas9. This evidence concerns the gene EGFR and glioblastoma.